Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879572 | 1.00 | MAPK14 (0.35) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL4879463 | 0.91 | SYK (0.36) | MAPK14ALDH1A1LMNASYKRAB9A | |
| SCHEMBL4879459 | 0.91 | SYK (0.36) | MAPK14ALDH1A1LMNASYKRAB9A | |
| SCHEMBL4878963 | 0.88 | SYK (0.35) | MAPK14ALDH1A1LMNASYKRAB9A | |
| SCHEMBL4878969 | 0.88 | SYK (0.35) | MAPK14ALDH1A1LMNASYKRAB9A | |
| SCHEMBL4879610 | 0.87 | MAPK14 (0.34) | MAPK14MAPK13MAPK12MAPK11CHRNA7 | |
| SCHEMBL4873533 | 0.87 | CHRNA7 (0.34) | MAPK14MAPK13MAPK12MAPK11RAB9A | |
| SCHEMBL4879615 | 0.87 | MAPK14 (0.34) | MAPK14MAPK13MAPK12MAPK11CHRNA7 | |
| SCHEMBL4873528 | 0.87 | CHRNA7 (0.34) | MAPK14MAPK13MAPK12MAPK11RAB9A | |
| SCHEMBL4878531 | 0.87 | MAPK14 (0.33) | MAPK14MAPK13MAPK12MAPK11RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | MAPK14 13/4885MAPK13 12/4885MAPK12 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.